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Background: Glandular lesions are often problematic for diagnostic cervical pathology. The survival of patients with
adenocarcinoma is significantly poorer than that of patient with squamous cell carcinoma. One reason for this
increased risk is the aggressive invasiveness of adenocarcinoma. Therefore additional biomarkers, to supplement
morphological diagnosis of adenocarcinoma, are necessary. We have assessed the diagnostic utility of Laminin-5
(Laminin γ2 chain): Lam-5 in the diagnosis of the invasiveness of cervical adenocarcinoma and related glandular
lesions.
Methods: Lam-5 immunohistochemistry was performed on archival specimens from 8 patients with uterine
leiomyoma as a negative control group, 6 patients with endocervical gland hyperplasia, 6 patients with
adenocarcinoma in situ, 6 patients with microinvasive adenocarcinoma and 24 patients with invasive
adenocarcinoma.
Results: The expression of Lam-5 was not detected in normal mucosa, but was seen along the basement
membrane in endocervical gland hyperplasia and adenocarcinoma in situ and was observed in the cytoplasm of
tumor cells in microinvasive and invasive adenocarcinoma.
Conclusion: We conclude that Lam-5 is a useful biomarker in the evaluation of invasiveness in cervical
adenocarcinoma.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7316562925827381
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Although adenocarcinoma (AC) is rare, relative to squa-
mous cell carcinoma (SCC), among uterine cervical can-
cers, the number of cases has increased in recent years,
particularly in young women [1]. Like SCC, invasive AC
is associated with high-risk human papillomavirus infec-
tion and arises from non-invasive precursors, namely
cervical glandular intraepithelial neoplasia/adenocarcin-
oma in situ [2]. The distinction between AC and SCC is
not only of academic interest since these glandular
lesions present many problems for diagnostic cervical* Correspondence: imura@med.u-toyama.ac.jp
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reproduction in any medium, provided the orpathology. Many different types of benign glandular
lesions of the endocervix increase the potential for cer-
vical neoplasia [3]. However, the distinguishing features
of AC and SCC have practical therapeutic and prognos-
tic implications, since the survival of patients with AC is
significantly poorer than that for patients with SCC. The
high invasiveness of tumor cells is the main reason for
poor prognosis in AC. Many factors affect the invasive-
ness of tumors. A wide variety of molecular markers
have been evaluated as diagnostic tools in the identifica-
tion of high-risk precursors of SCC and AC and the as-
sociation with cell adhesion molecules has attracted
attention recently. These molecules affect the protein
constitution of the basement membrane and play an im-
portant role in invasiveness.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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extracellular proteins and is among the components of
the basement membrane. The major functions of Lam-5
include binding of epithelial cells to the basement mem-
brane through the formation of hemidesmosomes [4]
and the migration of epithelial cells during wound re-
pair [5,6]. In addition, it has been reported that there is
a correlation between its expression and tumor progres-
sion in various kinds of malignant tumors [7-20].
According to some reports, Lam-5 is found in front-line
invasive tumor cells at the epithelial-stromal interface
and plays an important role in cancer cell invasion
[9,11,12,17-23]. Accumulating data indicates that Lam-
5 expression can serve as a marker for invasiveness in
carcinoma cells from different tissues [18,19,23]. In
uterine cervical cancers, recent data suggests that ex-
pression of Lam-5 could be a useful marker in the de-
tection of invasive squamous cell carcinoma [20]. A
more interesting finding, perhaps is that Lam-5 seems
to be expressed from the earliest stages, particularly in
microinvasive lesions.
Lam-5 may therefore become a very useful biomarker
of early invasion in the AC of the uterine cervix. The
aim of the present study was to assess whether Lam-5
can be used for evaluation of tumor cell invasiveness in
cervical AC and other precancerous lesions. We also
investigated whether Lam-5 can be used as a marker of
invasiveness in neoplastic lesions.
Methods
Cases
Each of our 50 cases were registered at the Department
of Surgical and Molecular Pathology, Dokkyo University
School of Medicine and the Department of Pathology,
Ibaraki Prefectural Central Hospital and were available
for clinicopathological and immunohistochemical ana-
lysis. The patients were staged clinically according to the
criteria of the International Federation of Gynecology
and Obstetrics: FIGO. Of the 42 tumors, 6 were glandu-
lar hyperplasia, 6 were adenocarcinoma in situ (TMN
Stage 0), 6 were microinvasive adenocarcinoma (Stage
Ia) and 24 were invasive carcinoma (Ib were 16 cases, II
were 5 cases and III were 3 cases).
Immunohistochemistry
The control specimens were normal tissues from 8 cases
of hysterectomy with diagnosis based on uterine leio-
myoma. We selected routinely-processed, formalin-fixed,
paraffin-embedded tissue blocks and prepared 5-
micrometer serial sections from the cut surface of the
blocks. Mouse monoclonal antibody (clone D4B45, Che-
micon 1:100) was used for the present immunohisto-
chemical study. Immunoperoxidase reactions were
performed using a Venta View automated immunostaineraccording to the manufacturer’s instructions. All cases
were reviewed by two investigators (JI and TF), and were
provided with a consensus on the pathological diagnoses
and the assessment of immunoreactivity.Results
No expression of Lam-5 was seen in normal endocervi-
cal glands and surrounding stroma (Figure 1A). Two of
6 cases (33%) of endocervical gland hyperplasia showed
linear or focal basement membrane expression of Lam-5
(Figure 1B). Five of 6 (83%) cases of ’adenocarcinoma in
situ’ showed continuous and linear Lam-5 expression
along the basement membrane (Figure 1C). All of the 6
cases (100%) of microinvasive adenocarcinoma produced
a positive reaction, with expression mainly present at the
invading front. Four of these cases evidenced cytoplas-
mic expression with the remainder linearly expressed
along the basement membrane. Cytoplasmic expression
was specifically seen in budding or dissociated cells from
tumor nests. Eighteen of 24 cases (75%) of invasive adeno-
carcinoma revealed cytoplasmic expression (Figure 1D).
Cytoplasmic expression was diffuse in most tumor cells
and scattered in the stroma. Linear expression along the
basement membrane surrounding tumor cells was also
observed in 11 of these cases. The immunohistochemical
findings are summarized in Table 1.Discussion
Laminins are a family of basement membrane proteins,
which associate with cell differentiation proteins, adhe-
sion and migration proteins, as well as being structural
components themselves [24-26]. Lam-5 is a recently
identified laminin isoform and is a disulfide-linked het-
erotrimer with precursor subunits of 200-, 155-, and
140-kDa. These precursors are rapidly processed by
cleavage of the 200- and 155-kDa subchains into 165-
and 105-kDd polypeptides, respectively [27]. Lam-5 is
known to be expressed in squamous cell carcinoma,
various adenocarcinomas and in organs such as the
esophagus, cervix, breast, colon and pancreas [7-20]. An
earlier study proposed that binding of the ligand to
urinary-type plasminogen activator receptor: uPAR pro-
motes cancer cell invasion by activation of plasminogen,
leading to the degradation of extracellular matrix [28].
The coexpression of Lam-5 and uPAR suggested Lam-5
may be useful as a marker of invasion in some human
cancers [18,23]. According to certain studies, Lam-5 is
found at the invasive front, along the epithelial-stromal
interface and plays an important role in cancer cell inva-
sion [9,11,12,17-23]. Sordat et al. [23] and Pyke et al.
[17,18] observed budding cancer cells linked with the ac-
cumulation of Lam-5 in the cytoplasm. In contrast,
extracellular Lam-5 expression has been reported in
Figure 1 Immunohistochemical findings for Laminin-5 in the normal mucosa and the lesions of uterine cervix. A. Normal mucosa: No
reaction in the endocervical glands. B. Endocervical gland hyperplasia and C. Adenocarcinoma in situ: Continuous and linear expression along
basement membrane. D. Invasive adenocarcinoma: The diffuse immunoreactivity in most of tumor cells is scattered in the stroma.
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cancer cells [11].
Lam-5 is expressed in hyperplastic tissue and most
tumors, but is not expressed in normal tissue. Although
the expression of Lam-5 was shown in a few glands with
endocervical hyperplasia, these cells might have already
acquired tumor characteristics without morphological
changes i.e. precursor cells derived from endocervical
glands that expressed Lam-5 might acquire tumor
characteristics.
Based on our results, we suggest that Lam-5 expres-
sion might be an early event during neoplastic progres-
sion towards AC. According to our hypothesis, the
upregulation of expression of Lam-5 might be related totumor progression, e.g. the adenoma-noninvasive carcin-
oma-invasive carcinoma sequence seen in colon carcino-
genesis. It seems clear from the literature that structural
changes in Lam-5 are relatively early events during the
development of invasiveness. On the other hand, the fre-
quency of Lam-5 expression decreased, to 75% in inva-
sive AC although it is 100% in microinvasive AC. This
interpretation is difficult, but Lam-5 may be expressed
at an early stage of the invasion. Furthermore the ex-
pression of Lam-5 might be attenuated in the later
phases when tumor cells are more extensively invasive.
Although the detailed molecular carcinogenic mechan-
ism is unknown, it does seem to be related to Lam-5 ex-
pression and the acquirement of invasiveness. Several
Table 1 Association between for laminin5 γ 2 chain






Normal 8 0 0 0
Hyperplasia 6 2 2 0
AIS 6 5 5 0
Microinvasive 6 6 2 4
Invasive 24 18 11 18
Normal: normal gland.
Hyperplasia: glandular hyperplasia.
AIS: adenocarcinoma in situ.
Microinvasive: microinvasive adenocarcinoma.
Invasive: invasive adenocarcinoma.
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expressed in epithelial cells at the invasive front of ma-
lignant tumors [9,11,12,17-23]. Other investigators also
describe how Lam-5 could become a useful biomarker
for the early detection of invasive tumor cells [20,29,30].
Cervical cancer is the second most common malig-
nancy in women worldwide [31]. Of the various histo-
logic subtypes, SCC is by far the most common form
while AC is relatively rare. In recent years, epidemiologic
studies have shown an increasing incidence of AC
worldwide [32], especially in younger patients [1,33]. AC
is a highly aggressive gynecologic malignancy. Over the
last several decades, the relative proportion of AC to
SCC of the uterine cervix has been increasing with sev-
eral studies reporting an increase in the absolute number
of AC cases [34]. In uterine cervical neoplasia, there are
many etiologies that explain why the AC patient has a
poorer prognosis than that of SCC [35]. One is the high
tendency for invasiveness of adenocarcinoma cells. It is
often hard to diagnose by colposcopy, cytodiagnosis and
punch biopsy, since AC tends to grow endophytically.
With regard to diagnosis, differentiation between adeno-
carcinoma in situ (FIGO 0), microinvasive (Ia), and inva-
sive adenocarcinoma (Ib) is an important and difficult
question to answer. The treatment strategy for patients
is different for adenocarcinoma in situ, microinvasive
adenocarcinoma and invasive adenocarcinoma. The pa-
tient will receive disease-specific treatments e.g. conization
in adenocarcinoma in situ, simple hysterectomy in micro-
invasive adenocarcinoma and radical hysterectomy with
additional lymphadenectomy in invasive adenocarcinoma.
It is often difficult to make this decision preoperatively.
We conclude in this article that the immunohistochemis-
try of Lam-5 is effective as a means to solve this problem.
Specifically, when cells expressing Lam-5 were observed
in the lesion by biopsy, we are able to surmise that those
cells are invasive. Therefore a simple hysterectomy and/or
more extensive surgery is indicated for these patients. Inaddition, even if the lesion was non-invasive in CIS mor-
phologically, these tumor cells might have acquired inva-
siveness when the cells express Lam-5. In such a case,
intensive follow-up care is required after treatment by
conization. Thus, a sensitive diagnostic procedure is a pre-
requisite for appropriate therapy.
Conclusion
It is only cases of microinvasive or invasive adenocarcin-
oma that have shown cytoplasmic immunoreactivity to
Lam-5. These findings are similar to other reports that
have compared immunoreactivity in different tumors,
particularly cervical squamous neoplasia. Our results in-
dicate that immunohistochemical expression of Lam-5 is
a useful marker for detecting invasive tumor cells in AC.
We can evaluate invasion in AC more precisely using
Lam-5 immunohistochemistry as an adjunct to morpho-
logical examination. This method could be useful in the
histopathological diagnosis of cervical cancer.
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